Our achievements. Our accomplishments. Our impact.



  • Drug Discovery and Repurposing

    The Stem Cell Network was among the first organizations to recognize the potential of using stem cells for drug repositioning and discovery in order to reduce time and costs of bringing new therapies to patients, and in the process has established Canada as a world leader in the field.

    READ STORY

  • Establishing a Community

    By prioritizing multidisciplinary research partnerships among stem cell researchers across Canada, the Stem Cell Network integrated the country’s previously fractured landscape into a comprehensive and globally respected research community.

    READ STORY

  • Stem Cell Genomics

    SCN’s Gene Expression Project was made possible through the Network’s collaborative approach to research, and the Project’s use of a single centre to undertake a standardized analysis of hundreds of stem cell lines allowed for the creation of pertinent data and meta-data to be accessed by thousands of researchers around the world.

    READ STORY

  • Commercialization

    The Stem Cell Network’s catalysis of commercialization of stem cell research has led to 399 patent applications, 60 issued patents, 43 licenses granted, the growth or launch of 11 start-up biotechnology companies and the establishment of a new Centre for the Commercialization of Regenerative Medicine (CCRM) to develop a strong industry presence in several emerging technology areas likely to be crucial to the future delivery of stem cell-based therapies.

    READ STORY

  • Patient Engagement

    The Stem Cell Network engaged world-leading researchers and ethicists to provide Canadians with credible and accessible information on the latest advancements in stem cell research.

    READ STORY

  • Cutting-Edge Skills Development

    The Stem Cell Network worked diligently to identify key areas where enhanced training, provided on a national scale, would have direct benefits on research outcomes and also for Canada’s future scientists and clinicians.

    READ STORY